18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease (Q43856186)

27 November 2017

18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease (English)

1 reference

27 November 2017

1 reference

6

1 reference

27 November 2017

Roberto Ceravolo

1

1 reference

27 November 2017

Paola Piccini

2

1 reference

27 November 2017

Dale L Bailey

3

1 reference

27 November 2017

Karin M Jorga

4

1 reference

27 November 2017

Helen Bryson

5

1 reference

27 November 2017

1 March 2002

1 reference

27 November 2017

1 reference

27 November 2017

43

1 reference

27 November 2017

3

1 reference

27 November 2017

201-207

1 reference

Extracellular concentrations of dopamine and metabolites in the rat caudate after oral administration of a novel catechol-O-methyltransferase inhibitor Ro 40-7592.

27 November 2017

1 reference

Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III.

21 January 2018

1 reference

Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients

21 January 2018

1 reference

3D acquisition and reconstruction in positron emission tomography

21 January 2018

1 reference

Differing patterns of striatal 18F-dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy

21 January 2018

1 reference

Pharmacokinetics of plasma 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine ([18F]Fdopa) in humans.

21 January 2018

1 reference

Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.

21 January 2018

1 reference

Dopamine visualized in the basal ganglia of living man.

21 January 2018

1 reference

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis

21 January 2018

1 reference

Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum.

21 January 2018

1 reference

18F‐6‐Fluorodopa PET scanning in Parkinson's disease after selective COMT inhibition with nitecapone (OR‐462)

21 January 2018

1 reference

Effect of catechol-O-methyltransferase inhibition on brain uptake of [18F]fluorodopa: implications for compartmental modelling and clinical usefulness.

21 January 2018

1 reference

Nigrostriatal function in humans studied with positron emission tomography

21 January 2018

1 reference

Plasma dopa concentrations after different preparations of levodopa in normal subjects

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of L-Dopa after acute and 6-week tolcapone administration in patients with Parkinson's disease

21 January 2018

1 reference

Tolcapone and hepatotoxic effects. Tasmar Advisory Panel

21 January 2018

1 reference

Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data

21 January 2018

1 reference

Cerebral 6-[18F]fluoro-L-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition.

21 January 2018

1 reference

Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients.

21 January 2018

1 reference

Detection of response to COMT inhibition in FDOPA PET in advanced Parkinson's disease requires prolonged imaging

21 January 2018

1 reference

The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson's disease

21 January 2018

1 reference

The presence of catechol-o-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells.

21 January 2018

1 reference

Comparison of two new inhibitors of catechol O-methylation on striatal dopamine metabolism: a microdialysis study in rats.

21 January 2018

1 reference

Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease.

21 January 2018

1 reference

Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase

21 January 2018

1 reference

Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-Dopa trapping in MPTP-induced parkinsonism in monkeys

21 January 2018

1 reference

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

21 January 2018

1 reference

Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson's disease.

21 January 2018

1 reference

Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats

21 January 2018

1 reference

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

Central action of benserazide after COMT inhibition demonstrated in vivo by PET

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/SYN.10034

1 reference

27 November 2017

1 reference